Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

被引：0

作者：

Samuel Murray

Vasilios Karavasilis

Mattheos Bobos

Evangelia Razis

Savvas Papadopoulos

Christos Christodoulou

Paris Kosmidis

George Fountzilas

机构：

[1] BioMarker Solutions Ltd,Department of Molecular Oncology

[2] GeneKOR,Department of Medical Oncology

[3] “Papageorgiou” Hospital,Department of Pathology

[4] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology

[5] Aristotle University of Thessaloniki School of Medicine,Department of Pathology

[6] “Hygeia” Hospital,Second Department of Medical Oncology

[7] “Hygeia” Hospital,Second Department of Medical Oncology

[8] “Metropolitan” Hospital,undefined

[9] “Hygeia” Hospital,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 31卷

关键词：

Predictive; Somatic mutation; EGFR; Gefitinib; Erlotinib; Response;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
Giandomenico Roviello
Laura Zanotti
Maria Rosa Cappelletti
Angela Gobbi
Martina Dester
Giovanni Paganini
Chiara Pacifico
Daniele Generali
Raheleh Roudi
Clinical and Experimental Medicine, 2018, 18 : 15 - 20
[32] Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer
Jia, Yijun
Li, Xuefei
Zhao, Chao
Jiang, Tao
Zhao, Sha
Zhang, Limin
Liu, Xiaozhen
Shi, Jinpeng
Qiao, Meng
Luo, Jiawei
Liu, Sangtian
Han, Ruoshuang
Chen, Xiaoxia
Zhou, Caicun
LUNG CANCER, 2018, 125 : 22 - 28
[33] Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
Jackman, David
Pao, William
Riely, Gregory J.
Engelman, Jeffrey A.
Kris, Mark G.
Jaenne, Pasi A.
Lynch, Thomas
Johnson, Bruce E.
Miller, Vincent A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) : 357 - 360
[34] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
Roviello, Giandomenico
Zanotti, Laura
Cappelletti, Maria Rosa
Gobbi, Angela
Dester, Martina
Paganini, Giovanni
Pacifico, Chiara
Generali, Daniele
Roudi, Raheleh
CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
[35] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer
Novello, Silvia
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 3985 - +
[36] EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
Kim, Edward S.
Melosky, Barbara
Park, Keunchil
Yamamoto, Nobuyuki
Yang, James C-H
FUTURE ONCOLOGY, 2021, 17 (18) : 2395 - 2408
[37] Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis
Lan, Chou-Chin
Hsieh, Po-Chun
Huang, Chun-Yao
Yang, Mei-Chen
Su, Wen-Lin
Wu, Chih-Wei
Wu, Yao-Kuang
WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (19) : 6360 - 6369
[38] Tyrosine kinase inhibitors in the management of non-small cell lung cancer
Perol, M.
Arpin, D.
REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S188 - S197
[39] Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer
De Luca, A.
Normanno, N.
CURRENT DRUG TARGETS, 2010, 11 (07) : 851 - 864
[40] Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
Courtin, Aurelie
Smyth, Tomoko
Hearn, Keisha
Saini, Harpreet K.
Thompson, Neil T.
Lyons, John F.
Wallis, Nicola G.
BRITISH JOURNAL OF CANCER, 2016, 115 (09) : 1069 - 1077

← 1 2 3 4 5 →